Navigation Links
ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
Date:9/19/2012

BARCELONA, Spain, September 19, 2012 /PRNewswire/ --

ESTEVE's R & D team includes a total of 350 people, 13% of the total global workforce, with the capability to work in all areas of drug discovery and the development of new medicines. This new R&D Center will house 92 scientists focused on two key phases in drug development; (1) The discovery phase, the phase during which new chemical entities are identified that may have the ability to positively change the course of a disease and, (2) the preclinical development phase, which includes performing all the necessary tests to provide the appropriate evidence to allow a new drug to be evaluated in humans.

The transfer to the PCB is an example of ESTEVE's commitment to research, despite the difficult socio-economic environment, as a way to maintain long-term sustainability. One of the keys to this sustainability is the ability to provide innovative solutions to medical needs that have not yet been adequately met. In this new facility, the company expects to increase performance in its R & D activities, improving the overall productivity of the discovery process in the development of new drugs and shorten the time to market.

This is the first alliance of its kind, where a large pharmaceutical company will locate all key competence units for drug discovery and preclinical development in a top quality academic / scientific environment in Spain.

The decision-making process to transfer the R & D team to the PCB took into consideration several factors, the most notable of which is the excellent infrastructure, the advantages of working in a high quality scientific and technical environment and the presence, in a common area, of scholars, researchers, talented young people and groups of entrepreneurs. It represents a further step towards a single model of open innovation in pharmaceutical R & D. ESTEVE's key strategy in R & D is an active policy of creating strategic alliances with universities, public research centres, technology companies and other companies in the sector, both in Spain and abroad

For more information go to http://www.esteve.com/investigacion-desarrollo


'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
(Date:5/23/2016)... 2016 According to a ... by Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, ... Care, Wound), Accessories (Lifting, Transfer) & by End ... by MarketsandMarkets, the patient handling equipment market is ... at a CAGR of 10.5% during the forecast ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million ... million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will ... Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... 2016 , ... North Cypress Medical Center hosted its 9th Annual ... With the help of community partners, the event organizers raised $45,000 for the ... service members and their families through health, wellness, and therapeutic support. , A ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading ... PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power ... the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The introduction of ... ADDING PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce ... the football front we have Brian Quick, wide receiver for Los Angeles who was ...
Breaking Medicine News(10 mins):